MeiraGTx's innovative gene therapies for ocular diseases & more are backed by strong clinical data and funding. Click here to find out why MGTX stock is a Buy.

Zoonotic and other infectious diseases are emerging and reemerging rapidly in recent times owing to altered climatic conditions, changing lifestyles, and unhealthy living conditions. The WHO listed 20 ...

DelveInsight's "LUXTURNA Market Size, Forecast, and Market Insight Report" highlights the details around LUXTURNA, a one-time ...

LUXTURNA has significant market potential due to the high unmet need for effective treatments in rare genetic conditions. With its FDA approval for specific mutations in the RPE65 gene, it offers ...

To participate in the call, please dial 833-816-1132 (Toll-Free/North America) or 412-317-0711 (International/Toll) and ask for the IMUNON Phase 3 protocol call. A live webcast of the call will also ...

Base editing corrected a mutation that causes macular degeneration, highlighting the potential of gene therapy to treat ...

Built around one of the most prolific academic viral vector manufacturing teams, ViroCell was created to address the global demand for precisely engineered viral vectors. The team leverages its ...

Medidata has launched the Medidata Site Insights Program, aimed at expediting the delivery of life-changing therapy to trial ...

Here’s the full story of how a joke about coriander led to an epic grocery delivery and a social media moment that everyone is still talking about! The tweet that kicked it off!! The fun didn ...

Genetic engineering in non-human primates has long been limited by the need for virus-based gene delivery methods. Recently, ...